Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd)

NCT03643965 is registered in ClinicalTrials.gov with Calliditas Therapeutics AB as lead sponsor.

NCT NCT03643965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03643965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd)
Lead sponsor
Calliditas Therapeutics AB
Phase
Phase 3
Overall status
Completed
Start date
September 5, 2018
Completion date
July 10, 2023
Enrollment
365 (actual)
Sites
142

Conditions

As the registry lists them; a condition with its own page is linked.

primary iga nephropathy